Hypermarcas takes over Farmasa and strengthens its medicines segment
Gazeta Mercantil - 06/03/2008
Little after its IPO is over, Hypermarcas already moves ahead with its audacious strategy of acquisitions of new brands to integrate its extensive portfolio, which ranges from hygiene and cleaning to beauty and foods, and most recently, medicines. Yesterday the company announced an agreement for the absorption of Laboratório Americano de Farmacoterapia S.A. (Farmasa). The deal, whose value has not been disclosed, involves the stock swap Hypermarcas, GP Investment and the Samaja family, thus creating the largest Brazilian pharmaceutical industry of over-the-counter (OTC) drugs, besides becoming the fifth largest national pharmaceutical industry and the seventh largest of the sector in Brazil, as announced. Hypermarcas was already inside this health segment since October, with the acquisition of DM Farmacêutica, which brought in its portfolio brands the Brazilians know very well such as Biotônico Fontoura, Melhoral, Engov, and Gelol. Everything suggests the plan now is to continue going forward, with the acquisition of names that are famous in the domestic territory such as the nasal solution Rinosoro, the laxative Tamarine, the liquid soap Lucretin, the analgesic Lisador or other brands that are, in some way, in the ostracism in the large portfolio of the pharmaceutical. industries According to the protocol sent this Monday to the Brazilian Securities & Exchange Commission (CVM), once the operation is complete, the capital stock of Hypermarcas, at the value of R$ 718.7 million (US$ 441 million), will be increased to R$ 1.592 billion (US$ 976.7 million), upon the issuance of 39,720,140 new common shares, which will be subscribed by the Farmasa shareholders.